Amends TCA Title 53; Title 63 and Title 68.

Tennessee HB0413 authorizes patients with severe chronic diseases or terminal illnesses to access investigational stem cell treatments that are still under clinical trial and not yet FDA-approved, provided certain criteria are met. The bill affects patients, their treating physicians, and regulatory bodies, establishing requirements for informed consent and protections for physicians against disciplinary actions related to their recommendations for such treatments. Additionally, it mandates the commissioner of health to create rules designating qualifying medical conditions and clarifies that the bill does not alter insurance coverage for clinical trials or violate existing laws regarding human tissue.